BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
288 hedge funds and large institutions have $9.81B invested in bluebird bio in 2019 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 106 increasing their positions, 79 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
15% more funds holding
Funds holding: 251 → 288 (+37)
0.13% more ownership
Funds ownership: 8.63% → 8.76% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
288
Holding in Top 10
1
Calls
$141M
Puts
$87.5M
Top Buyers
| 1 | +$74.9M | |
| 2 | +$58.4M | |
| 3 | +$49.1M | |
| 4 |
HM
HealthCor Management
New York
|
+$47.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.5M |
Top Sellers
| 1 | -$38.4M | |
| 2 | -$25.3M | |
| 3 | -$24.3M | |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.6M |
| 5 |
AG
Artal Group
Luxembourg
|
-$11.8M |